Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd is a Healthcare company operating in Biotechnology with a $3.39B market cap.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks TLPPF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 80% positive reaction rate
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TLPPF.
$ curl https://api.spokenalpha.com/v1/companies/TLPPFFAQ
Spoken Alpha indexes TLPPF's earnings call transcripts at https://spokenalpha.com/companies/TLPPF. Each call links to attributed speakers and parsed analyst Q&A. Telix Pharmaceuticals Ltd's own investor relations page is at https://ir.telixpharma.com/.
Telix Pharmaceuticals Ltd (TLPPF) operates in the Healthcare sector (Biotechnology industry).
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.29 | $1.85 | +23.6% | -3.4% | -2.2% |
| Q4 FY2026 | $2.08 | $1.59 | +31.0% | +3.7% | +1.1% |
| Q3 FY2026 | $2.36 | $1.77 | +33.3% | +0.3% | -2.6% |
| Q2 FY2026 | $2.50 | $1.83 | +36.5% | +4.4% | +2.3% |
| Q1 FY2025 | $2.14 | $1.65 | +29.6% | +5.6% | +8.5% |
| Q4 FY2025 |
| $2.24 |
| $1.71 |
| +31.2% |
| +4.0% |
| +3.1% |
| Q3 FY2025 | $2.37 | $1.83 | +29.5% | +0.4% | -1.7% |
| Q2 FY2025 | $2.51 | $1.87 | +34.1% | +2.1% | -0.4% |
| Q1 FY2024 | $2.55 | $1.92 | +32.7% | -5.3% | -6.0% |
| Q4 FY2024 | $2.34 | $1.83 | +27.7% | +3.0% | +3.2% |